Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder

References

• Lamm D, Herr H, Jakse G, Kuroda M, Mostofi FK, Okajima E, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998;4:130–8.
   PubMedGoogle Scholar
• Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 2014;65:267–9.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124–9.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53.
   PubMed Web of Science ®Google Scholar
• Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761–7.
   PubMed Web of Science ®Google Scholar
• Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol 2013;31:1635–42.
   PubMed Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. J Urol 2013;190:1200–4.
   PubMed Web of Science ®Google Scholar
• Gontero P, Fiorito C, Oderda M, Pappagallo G, Brausi M. Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol 2013;31:671–5.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742–50.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187–220.
   Web of Science ®Google Scholar
• Chade DC, Shariat SF, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 2010;184:464–9.
   PubMed Web of Science ®Google Scholar
• Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, et al. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int 2016;118:423–8.
   PubMedGoogle Scholar
• Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Duvdevani M, Shapiro A. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. Urol Oncol 2009;27:258–62.
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008;5:11–16.
   PubMedGoogle Scholar
• Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 2014;66:694–701.
   PubMed Web of Science ®Google Scholar
• Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Malmström PU, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014;191:1244–9.
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Wijkström H, Rintala E, Mestad O, Jahnson S, Malmström PU. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol 2016;50:360–8.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol 2016;34:484.e19–.e25.
   Web of Science ®Google Scholar
• Yates DR, Brausi MA, Catto JWF, Dalbagni G, Rouprêt M, Shariat SF, et al. Treatment options available for bacillus Calmette-Guerin failure in non–muscle-invasive bladder cancer. Eur Urol 2012;62:1088–96.
   PubMed Web of Science ®Google Scholar
• Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 2013;63:145–54.
   PubMed Web of Science ®Google Scholar
• Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 2010;183:1757–63.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology 2006;68:538–42.
   PubMed Web of Science ®Google Scholar
• Zehnder P, Moltzahn F, Daneshmand S, Leahy M, Cai J, Miranda G, et al. Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy. BJU Int 2014;113:65–9.
   PubMed Web of Science ®Google Scholar